Know How Bexagliflozin Stacks Up to Other SGLT2 Inhibitors
New bexagliflozin (Brenzavvy) will try to shake up the SGLT2 inhibitor market.
That’s because bexagliflozin will cost about $50/mo...versus about $600/mo for other SGLT2 inhibitors (dapagliflozin, etc).
But bexagliflozin won’t be covered by most payers yet...and it will only be available through a single online pharmacy at first. Expect distribution to broaden over the next couple months.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote